{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-9275", "postId": 9275, "name": "Embecta Corp.", "description": "Faruqi & Faruqi, LLP Securities Litigation Partner\u00a0James (Josh) Wilson\u00a0Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in\u00a0Embecta\u00a0between November 25, 2025 and May 4, 2026\u00a0and would like to discuss your legal rights, call Faruqi & Faruqi partner\u00a0Josh Wilson directly\u00a0at\u00a0877-247-4292\u00a0or\u00a0212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (\u201cEmbecta\u201d or the \u201cCompany\u201d) (NASDAQ: EMBC) and reminds investors of the\u00a0August 17, 2026 deadline\u00a0to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Embecta’s fiscal results; pertinently, Embecta knew or recklessly disregarded that the Company’s guidance was misleading and unattainable. In fact, Embecta touted the Company’s pen needle business as “incredibly resolute” mere weeks prior to missing expectations and cutting 2026 fiscal guidance. Lead Plaintiff Deadline: August 17, 2026 \u00a0Call\u00a0Partner Josh Wilson\u00a0at\u00a0877-247-4292\u00a0or\u00a0212-983-9330 (Ext. 1310) Or\u00a0submit your information below\u00a0to learn about your rights.", "identifier": "EMBC", "legal": { "court": "District of New Jersey", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "11/25/2025", "end": "05/04/2026" }, "leadPlaintiffDeadline": "08/17/2026", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/embecta-corp/", "canonicalUrl": "https://faruqilaw.com/case/embecta-corp/", "datePublished": "2026-06-17T17:16:27+00:00", "dateModified": "2026-06-17T17:42:40+00:00", "associatedOrganization": { "@id": "case-9275-org" }, "legalService": { "@id": "case-9275-legalservice" }, "hasPart": [ { "@id": "case-9275-faq" }, { "@id": "case-9275-press-list" } ], "legalRepresentation": [ { "@id": "case-9275-attorney-516" }, { "@id": "case-9275-attorney-506" } ] }, { "@type": "Organization", "@id": "case-9275-org", "name": "Embecta Corp.", "identifier": "EMBC", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg" }, { "@type": "LegalService", "@id": "case-9275-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-9275-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-9275-legalservice" } }, { "@type": "Person", "@id": "case-9275-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-9275-legalservice" } }, { "@type": "FAQPage", "@id": "case-9275-faq", "mainEntity": [ { "@type": "Question", "name": "What is the Embecta securities class action lawsuit about?", "acceptedAnswer": { "@type": "Answer", "text": "The lawsuit alleges that Embecta Corp. (NASDAQ: EMBC) and certain of its executives made materially false and misleading statements to investors and concealed adverse facts about the company's true financial condition. The complaint specifically alleges that Embecta touted its pen needle business as \"incredibly resolute\" just weeks before reportedly missing its own guidance and cutting its fiscal year 2026 outlook." } }, { "@type": "Question", "name": "What happened to Embecta's stock price that triggered the lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "On May 5, 2026, Embecta disclosed second quarter 2026 results showing a revenue decline of over 14%, far exceeding the company's own guidance of flat to a decline of just 2%. Following that disclosure, Embecta's stock price allegedly fell from $9.25 per share to $3.90 per share in a single trading day, a decline of approximately 57.8%." } }, { "@type": "Question", "name": "Who is eligible to join the Embecta EMBC class action?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who purchased or otherwise acquired Embecta Corp. securities on the NASDAQ between November 25, 2025 and May 4, 2026, inclusive, may be eligible to participate. Eligibility to share in any potential recovery is not limited to those who seek a leadership role in the case \u2014 all qualifying class members may be entitled to participate regardless." } }, { "@type": "Question", "name": "What is the deadline to file a claim or take action in the Embecta lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "The deadline to seek appointment as lead plaintiff in the Embecta securities class action is August 17, 2026. Investors who wish to be considered for the lead plaintiff role must act before this date, though class members who do not seek that role are not required to file by this deadline in order to potentially share in any recovery." } }, { "@type": "Question", "name": "What does it mean to be a lead plaintiff in the Embecta class action?", "acceptedAnswer": { "@type": "Answer", "text": "A lead plaintiff is a court-appointed investor representative who directs and oversees the litigation on behalf of all class members, working with counsel on key decisions in the case. Courts generally appoint the movant with the largest financial interest in the litigation who also meets applicable legal requirements, though any eligible investor who purchased Embecta securities during the class period may apply." } }, { "@type": "Question", "name": "Do I have to be the lead plaintiff to recover money in the Embecta lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "No \u2014 investors do not need to seek or obtain lead plaintiff status in order to share in any recovery that may ultimately be obtained. All eligible class members who purchased Embecta securities between November 25, 2025 and May 4, 2026 may be entitled to participate in any settlement or judgment regardless of whether they take an active role in the litigation." } }, { "@type": "Question", "name": "What allegedly misleading statements did Embecta make about its pen needle business?", "acceptedAnswer": { "@type": "Answer", "text": "The complaint alleges that Embecta described its pen needle business as \"incredibly resolute\" to investors just weeks before the company reportedly missed its guidance and was forced to lower its fiscal year 2026 outlook. The lawsuit alleges that Embecta knew or recklessly disregarded that its publicly issued guidance was misleading and unattainable at the time those statements were made." } }, { "@type": "Question", "name": "What should I do if I lost money on Embecta stock?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who purchased Embecta Corp. (NASDAQ: EMBC) shares between November 25, 2025 and May 4, 2026 and suffered losses are encouraged to review their brokerage and trading records and preserve all relevant documentation, including trade confirmations and account statements. Given the August 17, 2026 lead plaintiff deadline, investors with potential claims should consider consulting with securities counsel promptly to understand their legal options." } } ] }, { "@type": "NewsArticle", "@id": "case-9275-press-1", "headline": "Embecta Corp. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts", "url": "https://finance.yahoo.com/markets/stocks/articles/embecta-corp-reported-surprise-loss-152549663.html", "datePublished": "2026-05-09" }, { "@type": "NewsArticle", "@id": "case-9275-press-2", "headline": "Earnings call transcript: Embecta Q2 2026 sees sharp earnings miss, stock plunges", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-embecta-q2-2026-sees-sharp-earnings-miss-stock-plunges-93CH-4659125", "datePublished": "2026-05-06" }, { "@type": "NewsArticle", "@id": "case-9275-press-3", "headline": "Embecta Q2 FY2026 slides: sharp miss triggers guidance cut, stock plunge", "url": "https://www.investing.com/news/company-news/embecta-q2-fy2026-slides-sharp-miss-triggers-guidance-cut-stock-plunge-93CH-4659287", "datePublished": "2026-05-05" }, { "@type": "NewsArticle", "@id": "case-9275-press-4", "headline": "Embecta 'disappointed' with Q2 results that fell below expectations, cuts 2026 guidance", "url": "https://www.drugdeliverybusiness.com/embecta-disappointed-q2-2026-below-expectations/", "datePublished": "2026-05-05" }, { "@type": "NewsArticle", "@id": "case-9275-press-5", "headline": "Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)", "url": "https://seekingalpha.com/article/4848713-embecta-growth-stalls-despite-strong-fiscal-2025-results", "datePublished": "2025-11-29" }, { "@type": "NewsArticle", "@id": "case-9275-press-6", "headline": "Earnings Release: Here's Why Analysts Cut Their Embecta Corp. (NASDAQ:EMBC) Price Target To US$16.67", "url": "https://finance.yahoo.com/news/earnings-release-heres-why-analysts-104532035.html", "datePublished": "2025-11-28" }, { "@type": "ItemList", "@id": "case-9275-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-9275-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-9275-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-9275-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-9275-press-4" } }, { "@type": "ListItem", "position": 5, "item": { "@id": "case-9275-press-5" } }, { "@type": "ListItem", "position": 6, "item": { "@id": "case-9275-press-6" } } ] } ] }

Embecta Corp.

Embecta Corp.

Join Action
Case Details
Filed On: June 17, 2026
Ticker EMBC
Class Period 11/25/2025 - 05/04/2026
Lead Plaintiff Deadline 08/17/2026
Days Left to Seek Plaintiff
61

If you are an Embecta Corp. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Embecta between November 25, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Embecta’s fiscal results; pertinently, Embecta knew or recklessly disregarded that the Company’s guidance was misleading and unattainable. In fact, Embecta touted the Company’s pen needle business as “incredibly resolute” mere weeks prior to missing expectations and cutting 2026 fiscal guidance.

📞 Lead Plaintiff Deadline: August 17, 2026

💻 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action
Embecta Corp.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771